By Brian Irwin
When it comes to paradigm shifts, pharma and biotech aren’t traditionally ahead of the proverbial curve. I should know, right? Having spent the entire 2000’s as a rep, analyst, sales trainer, and district manager, there were times when ‘moving the needle’ seemed glacier-like. The predominant mindset (pre-patent expiry cliff) regarding a paradigm shift in pharma was...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Trinity Insights | The iPad’s Yet-To-Be-Determined Impact on Pharma
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account